Press Release

Diagnostic Antibodies Market – 2019 Industry Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive, Regional, And Global Industry Forecast To 2025

The Global Diagnostic Antibodies Market is likely to witness numerous growth opportunities with recent advancements in monoclonal antibodies. According to a report by Fortune Business Insights, titled “Diagnostic Antibodies Market Size, Share and Global Trend By Type, Application, End User and Geography Forecast till 2026,” the growth of this market is likely to take off in the coming years with exceptional advancements in antibody therapeutics.

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/sample/diagnostic-antibodies-market-100318

Monoclonal antibodies are used for diagnostic purposes in life-threatening diseases such as cancer. Monoclonal antibodies are developed by cloning of identical immune cells, aimed at generating unique parent cells. The exceptional properties of monoclonal antibodies are likely to result in their use in cancer diagnosis, a reversal of drug toxicity, and may also be useful in diagnosing myocardial infarctions.

Diagnostic Antibodies
Diagnostic Antibodies

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook and SWOT analysis:
• Aytu BioScience, Inc.,
• Agilent Technologies, Inc.,
• Boehringer Ingelheim International GmbH,
• Bio-Rad Laboratories, Inc.,
• Abcam plc.,
• F. Hoffmann-La Roche Ltd.,
• Abbott

The use of monoclonal antibodies in the diagnosis and treatment of several diseases have led to a growing emphasis on research and development (RandD) of diagnostic antibodies. Additionally, the contribution from regulatory antibodies in approvals of newer drug applications and methods of diagnosis are likely to favor the growth of the global diagnostic antibodies market in the forthcoming years.

ImmunoPrecise Receives Subcontract for Manufacture of ‘Rabbit Monoclonal Antibodies’

In 2019, ImmunoPrecise received a subcontract from Leidos Biomedical Research, Inc. for production of rabbit monoclonal antibodies using its B-cell platform. ImmunoPrecise has its own B-Cell select platform that allows screening of large panels of antibodies for functionality testing, thereby allowing to finalize the best possible diagnostic antibody from a host of options. ImmunoPrecise’s latest subcontract and operations may have a positive impact on the global market and their attractive product offerings are likely to favor the growth of the global diagnostic antibodies market in the forthcoming years.

Increasing Diagnostic Tools to Offer a Favorable Growth Environment

In 2018, the National Cancer Institute stated that around 1,735,350 cases of cancer were diagnosed in the U.S. The government has identified this as a severe problem and contributed swiftly in the form of cancer awareness programs and health reimbursement policies. Furthermore, there have been increasing approvals from regulatory organizations such as the Food and Drug Organization (FDA) for diagnostic tools for detecting tumor and other forms of cancer.

Additionally, increasing research activities for the development of anti-tumor antibodies are likely to boost the global diagnostic antibodies during the forecast period. Although diagnostic antibodies possess properties to detect several life-threatening diseases, research and studies have also singled out that the questions to some adverse effects still remain unanswered.

Request Customization of this [email protected] https://www.fortunebusinessinsights.com/enquiry/customization/diagnostic-antibodies-market-100318

Accounting to this, governments across a few nations are somewhat reluctant in promoting research processes of diagnostic tools and drugs for diagnostic antibodies. Along with the aforementioned factors, lack of healthcare infrastructure in emerging nations is likely to hamper the growth of the global diagnostic antibodies in the coming years.
Some of the leading companies that are operating in the global diagnostic antibodies market are Aytu BioScience, Inc., Agilent Technologies, Inc., Boehringer Ingelheim International GmbH, Bio-Rad Laboratories, Inc., Abcam plc., F. Hoffmann-La Roche Ltd., Abbott amongst others.

By Application:
· Hepatitis Diagnostics
· Tuberculosis Diagnostics
· Cancer Diagnostics
· Oncology Diagnostics
· HIV Diagnostics
· Infectious Disease Diagnostics

By Type:
· Monoclonal Antibodies
· Polyclonal Antibodies
· Recombinant Polyclonal Antibodies

Browse Full [email protected] https://www.fortunebusinessinsights.com/industry-reports/diagnostic-antibodies-market-100318

About Us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:
Fortune Business Insights Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: [email protected]

Tags

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close